Patient description: The patient is a 15 year old girl with the history of recurrent bilateral headache. The attacks come 2 times or more per week and each episode lasts around a day or a half. The pain is pulsating in quality and severe in intensity, causing trouble in her routine physical activity. The attacks are associated with nausea and photophobia. She recently noticed that that there are more attacks around her menstrual period. She is diagnosed with the migraine headache and is under treatment. She is a high-school student and living with her both parents. She is a book worm and spend her free time in a public library near her home. She is also interested in writing stories and has several short stories in English. She rarely does exercise. Her BMI is 21 with the BP of 100/60. There is nothing remarkable in her physical exam.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Nasopharyngeal Carcinoma Have the ability to understand and willingness to sign a written informed consent document 2. Identified as recurrent nasopharyngeal carcinoma or distant metastases of male or female subjects who had failed in 1st line therapy including radiotherapy, not suitable for radiotherapy or unwilling to receive radiotherapy, 1st line chemotherapy excluding gemcitabine, and no curative treatment options 3. Biopsy confirmed belong to World Health Organization classification of nasopharyngeal carcinoma type II or type III 4. Men and women between aged 20 to 80 years of age; female patients with childbearing potential will routinely consult obstetric doctor for contraception and need to have contraception at least 6 months after finished this trial 5. Adequate internal organs including liver, kidney and bone marrow function white blood cell count of >3,000/µL; platelet count of ≥100,000/µL; absolute neutrophil count >1,500/µL total bilirubin <2.0 mg/dL, aspartate aminotransferase (AST), alanine transaminase(ALT) <2.5x upper limit of normal range (ULN) serum creatinine <2.0 mg/dL 6. The daily performance status ECOG ≤ 2 points  Pregnancy or breast-feeding women, and plans within six months of pregnancy 2. Contraindication to Gemmis injection, Depakine gastro-resistant tablet, and Valcyte film-coated tablets, including Allergy to Gemmis injection, Depakine gastro-resistant tablet, Valcyte film-coated tablets, and other similar drugs Patients with hepatic B or C, patients with human immunodeficiency virus, or viral related disease receiving anti-viral treatment Acute or chronic hepatitis not related to NPC with liver metastasis Using drugs which ineligible combination with valproic acid, including mefloquine, St.-John's-Wort, lamotrigine, Topiramate, quetiapine, cyclosporin, hepatic enzyme-inducing drugs (e.g., phenytoin, carbamazepine phenobarbital, primidone, rifampin), enzyme inhibitors (e.g., felbamate), aspirin, cimetidine, erythromycin, carbapenem (e.g., Panipenem, Aztreonam, Imipenem, Meropenem), diazepam, ethosuximide, lamotrigine, phenytoin, nimodipine 3. With insomnia, anxiety or spiritual concerns, or are receiving mental illness treatment 4. Has been diagnosed with a second cancer, except to basal cell carcinoma 5. Patients unsuitable to this trial, including Patients with significant disease PI evaluated with high risk group patients Patients not recovered from previous anti-cancer treatment Recent major surgery 6. Patients with creatinine clearance rate <40 ml/min